Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q3 FY2018 Earnings Presentation
17 slides from Alkem Laboratories's earnings presentation, Feb 9, 2018
Slide 1: Alkem reports Q3FY18 and 9MFY18 Results (Press Release)
<a> ALKEM in ieve value driven leadership ALKEM LABORATORIES LTD. India To nHealth Care Industry and beyond.. Regd. Office : " ALKEM HOUSE", Senapati Bapat Marg, Through Lower Parel, Mumbai - 400 013. Phone : 022-3982 9999, Fax : 022-2495 2955 Quality that is infinite Email : contact@alkem.com Websi
Slide 2: Operational Highlights: Domestic Business
<a> ALKEM hip in To achieve value driven leaders beyond... ALKEM LABORATORIES LTD. re Industry and Regd. Office : " ALKEM HOUSE", Senapati Bapat Marg, Indian Health CaThrough ite Lower Parel, Mumbai - 400 013. Phone : 022-3982 9999, Fax : 022-2495 2955 Quality tbst is infin Email : contact@alkem.com
Slide 3: International Business, R&D and US FDA Inspections
ALKEM in ive leadership ALKEM LABORATORIES LTD. To achieve valueIndustry Health Care dr n and beyond—. Regd. Office : "ALKEM HOUSE", Senapati Bapat Marg, Indian Through Lower Parel, Mumbai - 400 013. Phone : 022-3982 9999, Fax : 022-2495 2955 Quality that is infinite Email : contact@alkem.com Websit
Slide 4: Q3FY18 and 9MFY18 Conference Call
<a> ALKEM To achieve value driven leadership in and beyond... ALKEM LABORATORIES LTD. Industry Indian Health Care Regd. Office : " ALKEM HOUSE", Senapati Bapat Marg, Through Lower Pare!, Mumbai - 400 013. Phone : 022-3982 9999, Fax 022-2495 2955 ality that is infinite QuService that cares Email : co
Slide 5: Investor Presentation Q3FY18 – 9th February 2018
Investor Presentation Q3FY18 – 9th February 2018
Slide 6: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 7: Key Highlights For The Quarter
Key Highlights For The Quarter Robust quarter – Strong revenue growth accompanied with improvement in EBITDA margins • India Business reported 22% YoY growth: Company maintained its leading positions in the acute therapy areas while improving its presence in the chronic therapy segments • Healthy gr
Slide 8: Key Financial Highlights – Q3FY18 (Consolidated)
Key Financial Highlights – Q3FY18 (Consolidated) All figures in Rs mn Total Revenue from Operations India sales 12,567 Adjusting for the 10,298 impact of GST, YoY 17,405 growth was even higher 14,819 Q3FY17 Q3FY18 International sales 4,660 4,324 Q3FY17 Q3FY18 Notes: Post implementation of GST with e
Slide 9: Key Financial Highlights – Q3FY18 (Consolidated)
Key Financial Highlights – Q3FY18 (Consolidated) All figures in Rs mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 11,141 3,598 9,414 2,681 63.5% 64.0% 18.1% 20.7% Q3FY17 Q3FY18 Q3FY17 Q3FY18 PBT (before Minority Interest) PAT (after Minority Interest) Reported Net Profit after tax impacte
Slide 10: Key Financial Highlights – 9MFY18 (Consolidated)
Key Financial Highlights – 9MFY18 (Consolidated) Particulars (Rs mn) 9MFY18 9MFY17 YoY growth Revenue from Operations 49,180 46,011 6.9% • Adjusting for the GST impact, the YoY revenue growth in 9MFY18 was higher Gross Profit 30,211 28,404 6.4% • Growth in the International Business was Gross Profit
Slide 11: India Business
India Business India Business: Q3FY18 Sales of Rs.12,567 million (22.0% growth YoY) • India sales contributed 73.0% to total sales in Q3FY18 • Adjusting for the GST impact, YoY growth during the quarter and nine months ending 31st December 2017 was even higher • The YoY growth during the quarter was
Slide 12: India Business – Secondary Sales Performance
India Business – Secondary Sales Performance Outperformance across all the major therapeutic areas in Q3FY18 Established therapeutic +2 Market rank 1 3 3 4 areas of Alkem 23.8% 19.5% 11.4% 13.3% 10.5% 9.4% 9.7% 7.7% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Al
Slide 13: US Business
US Business US Business: Q3FY18 Sales of Rs.3,592 million (6.1% growth YoY) • US sales contributed 20.9% to total sales in Q3FY18 • YoY growth during the quarter was higher in US$ terms • In Q3FY18, the Company filed 3 ANDAs with the US FDA and received 7 approvals (including 1 tentative approval) •
Slide 14: Other International Business
Other International Business Other International Business: Q3FY18 Sales of Rs.1,068 million (13.7% growth YoY) • Other International Market sales contributed 6.2% to total sales in Q3FY18 • Company’s key markets including Australia, Philippines, Chile and Kazakhstan recorded healthy growth for the q
Slide 15: Consistent Strategy, Strong Execution
Consistent Strategy, Strong Execution With a consistent strategy, the greater focus has been on stronger execution 1 India Sales: Consolidate Company’s leadership position in the acute segment by driving growth in its mega brands 2 India Sales: Increase Company’s market share in the chronic segment
Slide 16: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on 31st December 2017 Non-Institution, 27.55% Promoter & Promoter Group, Institution, 65.86% 6.59% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other B
Slide 17: Thank You
Thank You